Amica Pension Fund Board of Trustees Has $5.58 Million Holdings in Merck & Co. (MRK)

Amica Pension Fund Board of Trustees cut its stake in Merck & Co. (NYSE:MRK) by 18.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 99,155 shares of the company’s stock after selling 21,794 shares during the period. Amica Pension Fund Board of Trustees’ holdings in Merck & Co. were worth $5,579,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. NewSquare Capital LLC grew its stake in shares of Merck & Co. by 728.3% in the third quarter. NewSquare Capital LLC now owns 14,801 shares of the company’s stock worth $115,000 after purchasing an additional 13,014 shares in the last quarter. Stevens First Principles Investment Advisors grew its stake in shares of Merck & Co. by 79.3% in the fourth quarter. Stevens First Principles Investment Advisors now owns 2,080 shares of the company’s stock worth $117,000 after purchasing an additional 920 shares in the last quarter. Balentine LLC grew its stake in shares of Merck & Co. by 1.0% in the second quarter. Balentine LLC now owns 2,107 shares of the company’s stock worth $135,000 after purchasing an additional 20 shares in the last quarter. WealthTrust Arizona LLC grew its stake in shares of Merck & Co. by 103.7% in the fourth quarter. WealthTrust Arizona LLC now owns 2,495 shares of the company’s stock worth $140,000 after purchasing an additional 1,270 shares in the last quarter. Finally, Taylor Hoffman Wealth Management bought a new position in shares of Merck & Co. in the fourth quarter worth $156,000. 74.60% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

NYSE:MRK opened at $58.64 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.33 and a quick ratio of 1.06. Merck & Co. has a 1-year low of $52.83 and a 1-year high of $66.41. The firm has a market capitalization of $159,803.17, a P/E ratio of 14.73, a P/E/G ratio of 2.48 and a beta of 0.78.

Merck & Co. (NYSE:MRK) last released its quarterly earnings results on Friday, February 2nd. The company reported $0.98 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.04. Merck & Co. had a return on equity of 28.61% and a net margin of 6.40%. The business had revenue of $10.43 billion during the quarter, compared to analyst estimates of $10.48 billion. During the same quarter last year, the company posted $0.89 EPS. Merck & Co.’s revenue for the quarter was up 3.1% on a year-over-year basis. research analysts expect that Merck & Co. will post 4.16 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, April 6th. Investors of record on Thursday, March 15th were given a $0.48 dividend. The ex-dividend date of this dividend was Wednesday, March 14th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.27%. Merck & Co.’s dividend payout ratio (DPR) is 48.24%.

In related news, Director Wendell P. Weeks sold 5,000 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $53.57, for a total value of $267,850.00. Following the completion of the transaction, the director now owns 5,100 shares in the company, valued at approximately $273,207. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Weir Mirian M. Graddick sold 24,000 shares of the stock in a transaction on Monday, April 16th. The shares were sold at an average price of $58.00, for a total value of $1,392,000.00. The disclosure for this sale can be found here. Company insiders own 0.32% of the company’s stock.

MRK has been the subject of several recent analyst reports. Barclays raised Merck & Co. from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $62.00 to $64.00 in a research note on Thursday, April 5th. SunTrust Banks raised Merck & Co. from a “hold” rating to a “buy” rating and increased their price target for the stock from $54.00 to $72.00 in a research note on Tuesday, January 16th. ValuEngine raised Merck & Co. from a “hold” rating to a “buy” rating in a research note on Wednesday, January 10th. BMO Capital Markets raised their target price on Merck & Co. from $68.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, January 17th. Finally, DZ Bank raised Merck & Co. from a “hold” rating to a “buy” rating in a research note on Tuesday, February 13th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $66.83.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/20/amica-pension-fund-board-of-trustees-has-5-58-million-holdings-in-merck-co-mrk.html.

About Merck & Co.

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply